Related Experiment Video
Updated: Mar 13, 2026
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Past, Present and Future of Regenerative Gene Therapy for Ischemic Heart Failure
Laura Florit Gonzalez1, Mara Bouwman1, Jeroen Bakkers2,3
1Hubrecht Institute of Developmental Biology, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands.
Insights
Gene therapy offers new hope for ischemic heart failure by targeting molecular mechanisms and regeneration. However, consistent clinical efficacy remains a challenge, necessitating improved preclinical models for effective cardiac repair.
Area of Science:
- Cardiovascular Research
- Molecular Medicine
- Regenerative Medicine
Background:
- Current heart failure therapies primarily manage symptoms and slow progression, lacking curative potential.
- Cardiovascular diseases are a leading cause of mortality, driving the need for effective treatments.
- Understanding cardiac regeneration pathways opens new avenues for treating heart failure.
Purpose of the Study:
- To review gene therapy strategies for ischemic heart failure.
- To highlight the role of preclinical models in translating research to clinical practice.
- To discuss emerging regenerative approaches for myocardial repair.
Main Methods:
- Review of current gene therapy strategies for ischemic heart failure.
- Emphasis on the importance of preclinical models.
- Discussion of emerging regenerative approaches.
Main Results:
- Gene therapy shows promise but faces challenges in clinical efficacy.
- Preclinical models are crucial for bridging the gap between research and clinical application.
- Regenerative approaches aim to repair damaged heart muscle and restore function.
Conclusions:
- Gene therapy and regenerative medicine represent promising frontiers for ischemic heart failure.
- Robust preclinical models are essential for successful clinical translation.
- Further research is needed to overcome challenges and improve patient outcomes.
Abstract:
Despite advances in heart failure management, current therapies largely focus on symptom relief and slowing disease progression, without reversing or preventing the underlying condition. As cardiovascular diseases remain a leading cause of mortality, developing curative treatments is an urgent goal. Advances in understanding the molecular mechanisms of heart failure, alongside insights into pathways that drive cardiac regeneration have opened new avenues for gene therapies aimed at restoring cardiac function. While several gene therapy candidates have advanced to clinical trials, their outcomes have been inconsistent, underscoring the challenge to translating preclinical success into clinical efficacy. In this review, we examine the current landscape of gene therapy strategies for ischemic heart failure, emphasize the importance of robust preclinical models in bridging the gap from bench to bedside, and highlight emerging regenerative approaches that aim to repair damaged myocardium and restore cardiac function.
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
00:59Gene Therapy
00:59Gene Therapy
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...